Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish women

References

• Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
   PubMed Web of Science ®Google Scholar
• The European Agency for the Evaluation of Medicinal Products. EMEA public statement on recent publications regarding hormone replacement therapy, December 3, 2003 (http://www.emea.europa.eu/pdfs/human/press/pus/3306503en.pdf). Accessed August 4, 2008
   Google Scholar
• Clarke C A, Glaser S L, Uratsu C S, et al. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006; 24: e49–e50
   PubMed Web of Science ®Google Scholar
• Glass A G, Lacey J V, Jr, Carreon J D, et al. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1152–1161
   PubMed Web of Science ®Google Scholar
• Jemal A, Ward E, Thun M J. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 2007; 9: R28
   PubMed Web of Science ®Google Scholar
• Kerlikowske K, Miglioretti D L, Buist D S, et al. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007; 99: 1335–1339
   PubMed Web of Science ®Google Scholar
• Ravdin P M, Cronin K A, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670–1674
   PubMed Web of Science ®Google Scholar
• Bouchardy C, Morabia A, Verkooijen H M, et al. Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. BMC Cancer 2006; 6: 78
   PubMed Web of Science ®Google Scholar
• Allemand H, Seradour B, Weill A, et al. [Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend]. Bull Cancer 2008; 95: 11–15
   PubMed Web of Science ®Google Scholar
• Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008; 107: 427–430
   PubMed Web of Science ®Google Scholar
• McNeil C. Breast cancer decline mirrors fall in hormone use, spurs both debate and research. J Natl Cancer Inst 2007; 99: 266–267
   PubMed Web of Science ®Google Scholar
• Hickey M, Davis S R, Sturdee D W. Treatment of menopausal symptoms: what shall we do now. Lancet 2005; 366: 409–421
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103–111
   PubMed Web of Science ®Google Scholar
• Flesch-Janys D, Slanger T, Mutschelknauss E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008; 123: 933–941
   PubMed Web of Science ®Google Scholar
• Lee S A, Ross R K, Pike M C. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005; 92: 2049–2058
   PubMed Web of Science ®Google Scholar
• Kumle M, Weiderpass E, Braaten T, et al. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1375–1381
   PubMed Web of Science ®Google Scholar
• Ekman A, Dickman P W, Klint A, et al. Feasibility of using web-based questionnaires in large population-based epidemiological studies. Eur J Epidemiol 2006; 21: 103–111
   PubMed Web of Science ®Google Scholar
• Thunell L, Milsom I, Schmidt J, et al. Scientific evidence changes prescribing practice – a comparison of the management of the climacteric and use of hormone replacement therapy among Swedish gynaecologists in 1996 and 2003. BJOG 2006; 113: 15–20
   PubMed Web of Science ®Google Scholar
• Thunell L, Stadberg E, Milsom I, et al. Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval. Acta Obstet Gynecol Scand 2005; 84: 395–401
   PubMed Web of Science ®Google Scholar
• Ekstrom H. Trends in middle-aged women's reports of symptoms, use of hormone therapy and attitudes towards it. Maturitas 2005; 52: 154–164
   PubMed Web of Science ®Google Scholar
• Li C, Borgfeldt C, Samsioe G, et al. Background factors influencing somatic and psychological symptoms in middle-age women with different hormonal status. A population-based study of Swedish women. Maturitas 2005; 52: 306–318
   PubMed Web of Science ®Google Scholar
• Hersh A L, Stefanick M L, Stafford R S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004; 291: 47–53
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–613
   PubMed Web of Science ®Google Scholar
• Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007; 63: 843–849
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–1059
   PubMed Web of Science ®Google Scholar
• Collins J A, Blake J M, Crosignani P G. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005; 11: 545–560
   PubMed Web of Science ®Google Scholar
• Banks E, Beral V, Cameron R, et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat 2001; 6: 357–363
   PubMedGoogle Scholar
• Sandini L, Pentti K, Tuppurainen M, et al. Agreement of self-reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study. Menopause 2008; 15: 282–289
   PubMed Web of Science ®Google Scholar